Advertisement

Topics

Galectin Therapeutics, Inc. Company Profile

12:00 EDT 25th June 2018 | BioPortfolio

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company’s unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.


PubMed Articles [504 Associated PubMed Articles listed on BioPortfolio]

Extracellular galectin-1 enhances adhesion to and invasion of oral epithelial cells by Porphyromonas gingivalis.

Galectin-1 and galectin-3 are C-type lectin receptors that bind to lipopolysaccharide (LPS) in the cell wall of gram-negative bacteria. In this study, we investigated the effects of galectin-1 and gal...

Evaluation of galectin-1 and galectin-3 as prospective biomarkers in keratoconus.

To evaluate the expression of β-galactoside-binding proteins galectin (Gal)-1 and Gal-3 in patients with keratoconus (KC) and postcorneal collagen cross-linking (CXL) treatment in vitro.

Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).

Galectin-3 is a member of the galectin family, which are β‑galactoside‑binding lectins with ≥1 evolutionary conserved carbohydrate‑recognition domain. It binds proteins in a carbohydrate‑de...

Galectin-3, a potential therapeutic target for rheumatoid arthritis?

Recently, we read with great interest the article by Issa, et al., who showed that baseline galectin-3 was significantly increased in anti-CCP positive rheumatoid arthritis (RA) patients when compare...

Noninvasive small-animal imaging of galectin-1 upregulation for predicting tumor resistance to radiotherapy.

Increasing evidence indicates that the overexpression of galectin-1, a member of the galectin family, is related to tumor progression and invasion, as well as tumor resistance to therapies (e.g., radi...

Clinical Trials [153 Associated Clinical Trials listed on BioPortfolio]

Blocking Extracellular Galectin-3 in Patients With Osteoarthritis

The proposed study is a pilot, double-blind, randomized clinical trial comparing galectin-3 inhibition with MCP to placebo for the treatment of knee osteoarthritis.

KERatoconus and Metalloproteinases InvesTigation

Corneal stromal thinning observed in keratoconic eyes could result from an increased synthesis of MMP at the level of the anterior stroma and the corneal epithelium induced by an overexpre...

Metalloproteinases and Recurrent Corneal Erosion Syndrome

Recurrent corneal erosion (RCE) syndrome can be observed either in the context of a dystrophy of the basement membrane or following corneal trauma. This syndrome is characterized by recurr...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Companies [1239 Associated Companies listed on BioPortfolio]

Galectin Therapeutics Inc.

Galectin Therapeutics is focusing its galectin inhibitor development efforts in two key disease areas: fibrosis and cancer.

Galecto Biotech AB

Galectin-3 is a member of the galectin family of galactoside binding lectins. Galectin-3 exists both intra- and extracellularly and binds to glycosylated proteins. Galectin-3 has ...

Galectin Therapeutics, Inc.

Galectin Therapeutics (OTC: GALT) is developing promising carbohydrate-based therapies for fibrotic liver disease and cancer based on the Company’s unique understanding of ga...

Pro-Pharmaceuticals, Inc.

Pro-Pharmaceuticals, OTCBB: PRWP, is the leader in the field of Galectin therapeutics and is engaged in the discovery, development and commercialization of therapeutics that targe...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Galectin Therapeutics, Inc." on BioPortfolio

We have published hundreds of Galectin Therapeutics, Inc. news stories on BioPortfolio along with dozens of Galectin Therapeutics, Inc. Clinical Trials and PubMed Articles about Galectin Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Galectin Therapeutics, Inc. Companies in our database. You can also find out about relevant Galectin Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...


Corporate Database Quicklinks



Searches Linking to this Company Record